Voyager Therapeutics Inc (VYGR) - Total Assets
Based on the latest financial reports, Voyager Therapeutics Inc (VYGR) holds total assets worth $288.31 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Voyager Therapeutics Inc - Total Assets Trend (2013–2024)
This chart illustrates how Voyager Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Voyager Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Voyager Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Voyager Therapeutics Inc's total assets of $288.31 Million consist of 70.4% current assets and 29.6% non-current assets. Review VYGR liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.2% |
| Accounts Receivable | $4.49 Million | 1.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Voyager Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See VYGR share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Voyager Therapeutics Inc's current assets represent 70.4% of total assets in 2024, a decrease from 90.6% in 2013.
- Cash Position: Cash and equivalents constituted 18.2% of total assets in 2024, down from 90.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 1.1% of total assets.
Voyager Therapeutics Inc Competitors by Total Assets
Key competitors of Voyager Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $547.14 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Kailera Therapeutics, Inc. Common Stock
NASDAQ:KLRA
|
USA | $1.21 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $512.24 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Voyager Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.19 | 8.45 | 7.39 |
| Quick Ratio | 6.19 | 8.45 | 7.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $184.09 Million | $329.23 Million | $171.00 Million |
Voyager Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Voyager Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.12 |
| Latest Market Cap to Assets Ratio | 0.38 |
| Asset Growth Rate (YoY) | 11.9% |
| Total Assets | $393.05 Million |
| Market Capitalization | $149.01 Million USD |
Valuation Analysis
Below Book Valuation: The market values Voyager Therapeutics Inc's assets below their book value (0.38x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Voyager Therapeutics Inc's assets grew by 11.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Voyager Therapeutics Inc (2013–2024)
The table below shows the annual total assets of Voyager Therapeutics Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $393.05 Million | +11.89% |
| 2023-12-31 | $351.28 Million | +120.44% |
| 2022-12-31 | $159.36 Million | -17.80% |
| 2021-12-31 | $193.85 Million | -25.89% |
| 2020-12-31 | $261.58 Million | -26.26% |
| 2019-12-31 | $354.76 Million | +100.40% |
| 2018-12-31 | $177.03 Million | -4.04% |
| 2017-12-31 | $184.48 Million | -2.68% |
| 2016-12-31 | $189.57 Million | -17.38% |
| 2015-12-31 | $229.46 Million | +1895.80% |
| 2014-12-31 | $11.50 Million | +7616.11% |
| 2013-12-31 | $149.00K | -- |
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene the… Read more